At WOC 2018, José Cunha-Vaz (University of Coimbra, Coimbra, Portugal) discussed his experience with treating patients with DME. The most significant developments in the area of DME are OCT imaging and the availability of anti-VEGF agents, which completely revolutionised treatment. The major issue is individualising treatment to each patient, as response varies greatly between different patients. The challenge is to understand how and which patients will respond to therapies. New drugs are currently on the horizon, which will offer new and better solutions to patients.
1. What have been the most significant recent developments in the area of DME? (1:02)
2. Discuss the current unmet needs and/or the challenges you face when treating patients with DME. (2:00)
3. What developments are you most excited about in the area of DME over the next few years? (3:20)
Share this Video
Related Videos In Retina/Vitreous
J Fernando Arevalo, AAO 2020 – Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms
It was a pleasure to catch up with our valued Editorial Board member, J Fernando Arevalo (Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA), who gave his insights on his topic at the retina subspecialty day at AAO 2020, intravitreal anti-VEGF injections for exudative retinal arterial macroaneurysms. Questions Could you give […]
Tommaso Rossi, EURETINA 2020 – Novel Instrument for Internal Limiting Membrane
We were delighted to catch up with Prof. Tommaso Rossi, who talked us through his presentation at EURETINA 2020 concerning a novel instrument for internal limiting membrane, amniotic and retinal flap manipulation. Questions What is the rationale for the use of amniotic membrane grafts in vitreoretinal surgery, and in what ophthalmic indications are they used? […]
Peter Stalmans, EURETINA 2020 – End-stage Retinitis Pigmentosa Patients Implanted with 3D–neural Interface Retinal Prosthesis
Prof. Peter Stalmans (University Hospitals, Leuven, Belgium) talked us through his presentation at EURETINA on first reported clinical results from end-stage retinitis pigmentosa patients implanted with an innovative 3D neural interface retinal prosthesis. Questions Could you give us an overview of advances in retinal prosthesis approaches in the treatment of advanced retinitis pigmentosa […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!